Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001685071-19-000015
Filing Date
2019-05-07
Accepted
2019-05-07 07:16:17
Documents
66
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q dovaq1201910-q.htm 10-Q 671350
2 EXHIBIT 10.2 dovaq12019ex102.htm EX-10.2 450463
3 EXHIBIT 31.1 dovaq12019ex311.htm EX-31.1 12798
4 EXHIBIT 31.2 dovaq12019ex312.htm EX-31.2 12776
5 EXHIBIT 32.1 dovaq12019ex321.htm EX-32.1 8974
  Complete submission text file 0001685071-19-000015.txt   4471744

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT dova-20190331.xml EX-101.INS 540374
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dova-20190331.xsd EX-101.SCH 45339
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dova-20190331_cal.xml EX-101.CAL 56594
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dova-20190331_def.xml EX-101.DEF 232419
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dova-20190331_lab.xml EX-101.LAB 586471
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dova-20190331_pre.xml EX-101.PRE 341789
Mailing Address 240 LEIGH FARM ROAD DURHAM NC 27707
Business Address 240 LEIGH FARM ROAD DURHAM NC 27707 919-806-4487
Dova Pharmaceuticals Inc. (Filer) CIK: 0001685071 (see all company filings)

EIN.: 813858961 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38135 | Film No.: 19801215
SIC: 2834 Pharmaceutical Preparations